Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.47 |
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | DRD3 | P35462 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399067 | 0.83 | KDM4E (0.49) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL2397624 | 0.81 | HTR1B (0.41) | MEN1KMT2ATDP1KDM4EHTR6 | |
| SCHEMBL12270756 | 0.81 | PPARG (0.44) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL13383648 | 0.76 | DRD4 (0.46) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL12266403 | 0.76 | DRD4 (0.46) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL12270753 | 0.74 | DRD4 (0.44) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL2401500 | 0.74 | KDM4E (0.46) | MEN1KMT2ATDP1KDM4E | |
| SCHEMBL2397641 | 0.72 | LYPLA1 (0.57) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL2407948 | 0.72 | DRD4 (0.49) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL11701339 | 0.70 | DRD4 (0.77) | DRD4DRD2DRD3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | DRD4 4304/4885DRD2 3904/4885DRD3 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.